Literature DB >> 24920800

Stabilizing the native trimer of HIV-1 Env by destabilizing the heterodimeric interface of the gp41 postfusion six-helix bundle.

Sannula Kesavardhana1, Raghavan Varadarajan2.   

Abstract

UNLABELLED: The HIV-1 envelope glycoprotein (Env) is a trimer of gp120-gp41 heterodimers and is essential for viral entry. The gp41 subunit in native, prefusion trimeric Env exists in a metastable conformation and attains a stable six-helix bundle (6-HB) conformation comprised of a trimer of N-heptad repeat (NHR) and C-heptad repeat (CHR) heterodimers, that drives the fusion of viral and cellular membranes. We attempted to stabilize native Env trimers by incorporation of mutations at the NHR-CHR interface that disrupt the postfusion 6-HB of gp41. The mutations V570D and I573D stabilize native Env of the HIV-1 JRFL strain and occlude nonneutralizing epitopes to a greater extent than the previously identified I559P mutation that is at the interface of the NHR trimers in the 6-HB. The mutations prevent soluble-CD4 (sCD4)-induced gp120 shedding and 6-HB formation. In the context of cell surface-expressed JRFL Env, introduction of a previously reported additional disulfide between residues A501 and T605 perturbs the native conformation, though this effect is partially alleviated by furin coexpression. The data suggest that positions 570 and 573 are surface proximal in native Env and that the NHR homotrimeric coiled coil in native Env terminates before or close to residue 573. Aspartic acid substitutions at these positions stabilize native trimers through destabilization of the postfusion 6-HB conformation. These mutations can be used to stabilize Env in a DNA vaccine format. IMPORTANCE: The major protein on the surface of HIV-1 is the envelope (Env) glycoprotein. Env is a trimer of gp120-gp41 heterodimers. gp120 is involved in receptor/coreceptor binding and gp41 in the fusion of viral and cellular membranes. Like many other viral fusion proteins, the gp41 subunit in native trimeric Env exists in a metastable conformation. gp41 readily forms a stable six-helix bundle (6-HB) conformation comprised of a trimer of N-heptad repeat (NHR) and C-heptad repeat (CHR) heterodimers that drives fusion of viral and cellular membranes. While it is expected that native Env is a good immunogen, its metastability results in exposure of immunodominant nonneutralizing epitopes. In the present study, we stabilize native Env trimers by incorporation of a number of different mutations at the NHR-CHR interface that disrupt the postfusion 6-HB of gp41. The stabilized constructs described here can be incorporated into DNA vaccine candidates.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24920800      PMCID: PMC4136328          DOI: 10.1128/JVI.00494-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Mutagenesis-based definitions and probes of residue burial in proteins.

Authors:  Kanika Bajaj; Purbani Chakrabarti; Raghavan Varadarajan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-26       Impact factor: 11.205

2.  Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion.

Authors:  Antony S Dimitrov; Amy Jacobs; Catherine M Finnegan; Gabriela Stiegler; Hermann Katinger; Robert Blumenthal
Journal:  Biochemistry       Date:  2007-02-06       Impact factor: 3.162

3.  Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1.

Authors:  Yun Kenneth Kang; Sofija Andjelic; James M Binley; Emma T Crooks; Michael Franti; Sai Prasad N Iyer; Gerald P Donovan; Antu K Dey; Ping Zhu; Kenneth H Roux; Robert J Durso; Thomas F Parsons; Paul J Maddon; John P Moore; William C Olson
Journal:  Vaccine       Date:  2009-06-28       Impact factor: 3.641

4.  Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Authors:  Simon Beddows; Norbert Schülke; Marc Kirschner; Kelly Barnes; Michael Franti; Elizabeth Michael; Thomas Ketas; Rogier W Sanders; Paul J Maddon; William C Olson; John P Moore
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

6.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

7.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

8.  Molecular architecture of native HIV-1 gp120 trimers.

Authors:  Jun Liu; Alberto Bartesaghi; Mario J Borgnia; Guillermo Sapiro; Sriram Subramaniam
Journal:  Nature       Date:  2008-07-30       Impact factor: 49.962

9.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

10.  Stereochemical criteria for prediction of the effects of proline mutations on protein stability.

Authors:  Kanika Bajaj; M S Madhusudhan; Bharat V Adkar; Purbani Chakrabarti; C Ramakrishnan; Andrej Sali; Raghavan Varadarajan
Journal:  PLoS Comput Biol       Date:  2007-12       Impact factor: 4.475

View more
  21 in total

1.  Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor.

Authors:  Nicole Espy; Beatriz Pacheco; Joseph Sodroski
Journal:  Virology       Date:  2017-05-15       Impact factor: 3.616

2.  SOSIP Changes Affect Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Conformation and CD4 Engagement.

Authors:  Nirmin Alsahafi; Sai Priya Anand; Luis Castillo-Menendez; Myriam Maude Verly; Halima Medjahed; Jérémie Prévost; Alon Herschhorn; Jonathan Richard; Arne Schön; Bruno Melillo; Ernesto Freire; Amos B Smith; Joseph Sodroski; Andrés Finzi
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

3.  Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.

Authors:  Ujjwal Rathore; Piyali Saha; Sannula Kesavardhana; Aditya Arun Kumar; Rohini Datta; Sivasankar Devanarayanan; Raksha Das; John R Mascola; Raghavan Varadarajan
Journal:  J Biol Chem       Date:  2017-04-26       Impact factor: 5.157

4.  Effects of the SOS (A501C/T605C) and DS (I201C/A433C) Disulfide Bonds on HIV-1 Membrane Envelope Glycoprotein Conformation and Function.

Authors:  Hanh T Nguyen; Nirmin Alsahafi; Andrés Finzi; Joseph G Sodroski
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

5.  SERINC5 Inhibits HIV-1 Infectivity by Altering the Conformation of gp120 on HIV-1 Particles.

Authors:  Austin Featherstone; Christopher Aiken
Journal:  J Virol       Date:  2020-09-29       Impact factor: 5.103

6.  Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors.

Authors:  Beatriz Pacheco; Nirmin Alsahafi; Olfa Debbeche; Jérémie Prévost; Shilei Ding; Jean-Philippe Chapleau; Alon Herschhorn; Navid Madani; Amy Princiotto; Bruno Melillo; Christopher Gu; Xin Zeng; Youdong Mao; Amos B Smith; Joseph Sodroski; Andrés Finzi
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

7.  Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies.

Authors:  Sannula Kesavardhana; Raksha Das; Michael Citron; Rohini Datta; Linda Ecto; Nonavinakere Seetharam Srilatha; Daniel DiStefano; Ryan Swoyer; Joseph G Joyce; Somnath Dutta; Celia C LaBranche; David C Montefiori; Jessica A Flynn; Raghavan Varadarajan
Journal:  J Biol Chem       Date:  2016-11-22       Impact factor: 5.157

8.  Conformational Differences between Functional Human Immunodeficiency Virus Envelope Glycoprotein Trimers and Stabilized Soluble Trimers.

Authors:  Luis R Castillo-Menendez; Hanh T Nguyen; Joseph Sodroski
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

9.  Modulating immunogenic properties of HIV-1 gp41 membrane-proximal external region by destabilizing six-helix bundle structure.

Authors:  Saikat Banerjee; Heliang Shi; Habtom H Habte; Yali Qin; Michael W Cho
Journal:  Virology       Date:  2016-01-21       Impact factor: 3.616

10.  Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers.

Authors:  Luis R Castillo-Menendez; Kristen Witt; Nicole Espy; Amy Princiotto; Navid Madani; Beatriz Pacheco; Andrés Finzi; Joseph Sodroski
Journal:  J Virol       Date:  2018-05-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.